EUVIMEDEUVIMED entdecken
Kohortenstudie

Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study

Kevin T Pritchard iD, Qiaoxi Chen iD, Kueiyu Joshua Lin iD, Tracey Simon iD

Clinical Pharmacology & Therapeutics · 2026

DOI: 10.1002/cpt.70223 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2026. Verfasst von Kevin T Pritchard und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massach…. Hauptthemen laut MEDLINE: Analgesics, Opioid, Liver Cirrhosis, Medicare, Chronic Pain. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Older adults with cirrhosis commonly experience chronic noncancer pain managed with chronic opioid therapy. Current guidelines recommend opioid deprescribing for high‐risk populations, including in cirrhosis, but data on tapering and discontinuation are scarce. We described opioid discontinuation rates and identified predictors of tapering or discontinuation. This retrospective cohort study of Medicare fee‐for‐service beneficiaries ( N = 800,763) ≥ 65 years with continuous opioid use for ≥ 90 days. The primary outcome was opioid discontinuation (i.e., a gap in refills > 30 days). The secondary outcome included opioid tapering (i.e., a 35% decrease in average daily morphine milligram equivalents; [yes/no]). The primary exposure was diagnosed cirrhosis severity (i.e., none, compensated, decompensated). We estimated discontinuation rates using the Kaplan–Meier method, time to opioid discontinuation using proportional hazards regression, and predictors of tapering with logistic regression. After 1 year, 37% (95% CI = 37–37%) of individuals without cirrhosis discontinued opioids, similar to those with compensated (36% (34–37%)) and decompensated (37% (35–39%)) cirrhosis. Age did not modify the adjusted association between cirrhosis status and discontinuation (Wald χ 2 (4) = 7.72, p = 0.10) but calendar year (pre/post COVID‐19) did (Wald χ 2 (1) = 26.57, p < 0.001). This finding indicated higher deprescribing rates prior to the pandemic, especially for those without cirrhosis (HR, 1.32; 95% CI, 1.31–1.33) compared with those with cirrhosis (HR, 1.13; 95% CI, 1.06–1.20). Non‐opioid analgesic use, fall history, and frailty significantly increased the odds of tapering. In conclusion, these findings may reflect a lack of safe analgesic alternatives or higher pain burden in cirrhosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidLiver CirrhosisMedicareChronic PainDeprescriptionsHumansRetrospective StudiesUnited StatesFemaleAgedMaleAged, 80 and overDrug Tapering

Substanzen

Analgesics, Opioid

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Kevin T Pritchard, Qiaoxi Chen, Kueiyu Joshua Lin, Tracey Simon

Zitieren

APA

Pritchard, K. T., Chen, Q., Lin, K. J., & Simon, T. (2026). Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.70223

Vancouver

Pritchard KT, Chen Q, Lin KJ, Simon T. Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study. Clinical Pharmacology & Therapeutics. 2026. doi:10.1002/cpt.70223

BibTeX
@article{Pritchard2026,
  author = {Pritchard, Kevin T and Chen, Qiaoxi and Lin, Kueiyu Joshua and Simon, Tracey},
  title = {Opioid Deprescribing Rates and Predictors Among Medicare Enrollees With Cirrhosis and Chronic Pain: Retrospective Cohort Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1002/cpt.70223}
}
Kostenlos starten →